Stocks
Immunome (IMNM) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 3 787% | 1 277% | 17 861% | 9 384% | 9 723% | 3 956% | |||
| Changes by years, y/y, % | +770pp | -2 509pp | +16 583pp | -8 477pp | +340pp | +26.4% | |||
Immunome. R&D/CAPEX, %
Immunome. R&D/CAPEX, changes, pp
Immunome (IMNM) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 10 619% | 25 840% | 5 872% | 1 241% | 435.7% | 3 956% | ||
| Changes by years, y/y, % | +19 935pp | +2 180pp | -440pp | -10 184pp | ||||
| Changes by quarters, q/q, % | +8 938pp | +15 221pp | -19 969pp | -4 631pp | -805pp | |||
